eflornithine has been researched along with Uterine Cervical Dysplasia in 8 studies
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.
Uterine Cervical Dysplasia: Abnormal development of immature squamous EPITHELIAL CELLS of the UTERINE CERVIX, a term used to describe premalignant cytological changes in the cervical EPITHELIUM. These atypical cells do not penetrate the epithelial BASEMENT MEMBRANE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (75.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vlastos, AT | 2 |
| West, LA | 1 |
| Atkinson, EN | 2 |
| Boiko, I | 2 |
| Malpica, A | 3 |
| Hong, WK | 3 |
| Follen, M | 3 |
| Boiko, IV | 2 |
| Mitchell, MF | 5 |
| Pandey, DK | 2 |
| White, RA | 1 |
| Hu, W | 2 |
| Nishioka, K | 5 |
| Boone, CW | 2 |
| Hittelman, WN | 3 |
| Tortolero-Luna, G | 2 |
| Lee, JJ | 2 |
| Lotan, R | 2 |
| Wharton, JT | 2 |
| Hittelman, WK | 1 |
| Mathevet, P | 1 |
| Poulin, N | 1 |
| MacAulay, C | 1 |
| Boone, C | 1 |
| Hittelman, W | 1 |
| Bacus, JW | 1 |
| Bacus, JV | 1 |
| Kelloff, GJ | 1 |
| Kagan, V | 1 |
| Lippman, SM | 1 |
| Zou, C | 1 |
| Yang, L | 1 |
| Wang, J | 1 |
3 trials available for eflornithine and Uterine Cervical Dysplasia
| Article | Year |
|---|---|
Results of a phase II double-blinded randomized clinical trial of difluoromethylornithine for cervical intraepithelial neoplasia grades 2 to 3.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Double-Blind Method; Eflornithine | 2005 |
Phase I dose de-escalation trial of alpha-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Arginine; Biogenic Polyamines; Dose-Response Rel | 1998 |
Nuclear morphometry as an intermediate endpoint biomarker in chemoprevention of cervical carcinoma using alpha-difluoromethylornithine.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Nucleus; Disease Progressio | 1999 |
5 other studies available for eflornithine and Uterine Cervical Dysplasia
| Article | Year |
|---|---|
DNA image cytometric measurement as a surrogate end point biomarker in a phase I trial of alpha-difluoromethylornithine for cervical intraepithelial neoplasia.
Topics: Adult; Anticarcinogenic Agents; Antineoplastic Agents; Clinical Trials, Phase I as Topic; DNA, Neopl | 1997 |
Polyamine measurements in the uterine cervix.
Topics: Cervix Uteri; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cohort Studies; | 1997 |
Epidermal growth factor receptor expression in cervical intraepithelial neoplasia and its modulation during an alpha-difluoromethylornithine chemoprevention trial.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Biomarkers; Cervix Uteri; Disease Progression; Eflor | 1998 |
Image morphometric nuclear grading of intraepithelial neoplastic lesions with applications to cancer chemoprevention trials.
Topics: Antineoplastic Agents; Biopsy; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Cell | 1999 |
Effects of difluoromethylornithine on growth inhibition and apoptosis in human cervical epithelial and cancerous cell lines.
Topics: Anticarcinogenic Agents; Apoptosis; Cell Division; Eflornithine; Female; Growth Inhibitors; Humans; | 2002 |